Daily Market Reports | Aug 18 2025
This story features LIFE360 INC, and other companies.
For more info SHARE ANALYSIS: 360
The company is included in ASX100, ASX200, ASX300, ALL-ORDS and ALL-TECH
An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities.
In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Australian Broker Call *Extra* Edition, featuring additional sources of research and insights on ASX-listed stocks, also enlarging the number of stocks that make up the FNArena universe.
One key difference is the *Extra* Edition will not be updated daily, but merely “regularly” depending on availability of suitable quality content. As such, the *Extra* Edition tries to build a bridge between daily updates via the Australian Broker Call Report and ad hoc news stories, that are not always timely for investors hungry for the next information update.
Investors using the *Extra* Edition as a source of input for their own share market research should thus take into account that information after publication may not be up to date, or yet awaiting another update by FNArena’s team of journalists.
Similar to The Australian Broker Call Report, this *Extra* Edition includes concise but limited reviews of research recently published by Stockbrokers and other experts, which should be considered as information concerning likely market behaviour rather than advice on the securities mentioned. Do not act on the contents of this Report without first reading the important information included at the end of this Report.
The Australian Broker Call *Extra* Edition is a summary that has been prepared independently of the sources identified. Readers will check the full text of the recommendations and consult a Licenced Advisor before making any investment decision.
The copyright of this Report is owned by the publisher. Readers will not copy, forward or disseminate this Report to any other person. For more vital information about the sources included, see the bottom of this Report.
COMPANIES DISCUSSED IN THIS ISSUE
Click on a symbol for fast access.
The number next to the symbol represents the number of brokers covering it for this report -(if more than 1)
360 AGN ALK AOV ARF ASK CBA EBR EVN GOZ IAG IFT LAM LGI LNW (2) MAP NAN ORA ORE ORG PLS PME (2) RHC S32 SGM SUN TAH TLS TPW (3) TWE VAU VGL (2) VNT WAF WBC
360 LIFE360 INC
Software & Services – Overnight Price: $43.34
Canaccord Genuity rates ((360)) as Buy (1) –
Canaccord Genuity assesses Life360’s 2Q25 result as strong with monthly active users up 4.3m q/q to 88m. Average revenue per subscription rose 7.5% y/y, driven by higher-priced membership tiers and improved mix.
Revenue rose 36% y/y to US$115.4m, beating consensus by 5% and adjusted EBITDA was ahead of consensus due to higher margin.
Overall, the broker highlights the company is sustaining strong subscription momentum and scaling advertising, while hardware remains steady. The 2Q outcome drove a guidance upgrade across revenue and EBITDA for FY25, with margins tracking ahead of expectations.
FY25 adjusted EBITDA lifted by 9.6% and FY26 by 5.3%.
Buy. Target lifted to USD$90 (was US$86 on July 27).
This report was published on August 11, 2025.
Current Price is $43.34. Target price not assessed.
Current consensus price target is $47.63, suggesting upside of 9.9%(ex-dividends)
The company’s fiscal year ends in December.
Forecast for FY25:
Canaccord Genuity forecasts a full year FY25 EPS of 44.86 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 96.60.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 71.4, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 60.7.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 EPS of 77.35 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 56.03.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 109.5, implying annual growth of 53.4%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 39.6.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.9
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
AGN ARGENICA THERAPEUTICS LIMITED
Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $0.73
Petra Capital rates ((AGN)) as Buy (1) –
Argenica Therapeutics’ ARG-007 new drug application was put on hold by the US FDA in June and now it has required for additional data to resolve the clinical hold.
Petra Capital reckons the requests are straightforward, low-cost and unlikely to derail timelines, given US trial is not expected until mid-2026.
The broker views the real driver for the stock as the September Phase 2 Seancon stroke trial results, which could meaningfully de-risk ARG-007 and attract partnerships in a large underserved market. Balance sheet is sufficient to reach this catalyst.
FY25 EPS forecast lifted but FY26 trimmed on timing of opex and tax rebate impact.
Buy. Target rises to $1.22 from $1.19.
This report was published on August 15, 2025.
Target price is $1.22 Current Price is $0.73 Difference: $0.49
If AGN meets the Petra Capital target it will return approximately 67% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY25:
Petra Capital forecasts a full year FY25 dividend of 0.00 cents and EPS of minus 4.30 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 16.98.
Forecast for FY26:
Petra Capital forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 4.70 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 15.53.
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
ALK ALKANE RESOURCES LIMITED
Gold & Silver – Overnight Price: $0.88
Moelis rates ((ALK)) as Buy (1) –
Moelis notes the highlight from Alkane Resources’ exploration update for Tomingley gold project was the El Paso deposit where the results were variable but showed strong peak grades and thickness.
The Tomingley structure didn’t reveal economic grades but did support potential for broader system scale, justifying follow-up drilling. The company is on track to deliver 170koz gold in FY26, the broker estimates.
The broker also commented on media report suggesting China’s refusal to forward shipment to US customer, noting it suggests the strategic importance of antimony as a critical mineral.
Buy. Target unchanged at $1.15.
This report was published on August 14, 2025.
Target price is $1.15 Current Price is $0.88 Difference: $0.27
If ALK meets the Moelis target it will return approximately 31% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY25:
Moelis forecasts a full year FY25 dividend of 0.00 cents and EPS of 5.70 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 15.44.
Forecast for FY26:
Moelis forecasts a full year FY26 dividend of 0.00 cents and EPS of 13.40 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 6.57.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
AOV AMOTIV LIMITED
Automobiles & Components – Overnight Price: $9.33
Canaccord Genuity rates ((AOV)) as Buy (1) –
Canaccord Genuity notes Amotiv’s FY25 revenue of $997.4m and underlying EBITDA of $192m were in line with adjusted guidance, the consensus and its forecasts.
Investor concerns remain around acquisition prices, particularly AutoPacific Group (APG) but the broker now believes both APG and 4WD are strategically valuable and should prove their worth over a 5-year-plus horizon.
The company has retained clients, renewed contracts, won new mandates, and broadly maintained or grown share. The broker expects earnings to recover through operational efficiency and cyclical upturn, but not in FY26.
FY27 EBITA downgraded by -1.3%, and underlying net profit for FY26 cut by -3.5% and for FY27 by -6.3%.
Buy. Target rises to $11.20 from $11.00.
This report was published on August 13, 2025.
Target price is $11.20 Current Price is $9.33 Difference: $1.87
If AOV meets the Canaccord Genuity target it will return approximately 20% (excluding dividends, fees and charges).
Current consensus price target is $11.62, suggesting upside of 24.5%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 42.00 cents and EPS of 86.00 cents.
At the last closing share price the estimated dividend yield is 4.50%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 10.85.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 84.5, implying annual growth of N/A.
Current consensus DPS estimate is 41.3, implying a prospective dividend yield of 4.4%.
Current consensus EPS estimate suggests the PER is 11.0.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 42.00 cents and EPS of 94.00 cents.
At the last closing share price the estimated dividend yield is 4.50%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 9.93.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 92.1, implying annual growth of 9.0%.
Current consensus DPS estimate is 46.2, implying a prospective dividend yield of 5.0%.
Current consensus EPS estimate suggests the PER is 10.1.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
ARF ARENA REIT
REITs – Overnight Price: $3.89
Jarden rates ((ARF)) as Buy (1) –
Jarden notes Arena REIT’s CEO succession announcement at the FY25 result was a surprise, with Justin Bailey appointed as part of a 18-24 succession process. The result showed solid capital structure, providing flexibility for acquisitions.
Net operating income grew 3.5% in FY25, and 10% of income is subject to rent reviews in FY26 and around 40% in the next four years. The broker sees scope for upside, given market rents are well below development economic rents.
Marginal cuts to FY26-28 FFO forecasts but target price rises to $4.60 from $4.55 on roll-forward. Buy retained.
This report was published on August 13, 2025.
Target price is $4.60 Current Price is $3.89 Difference: $0.71
If ARF meets the Jarden target it will return approximately 18% (excluding dividends, fees and charges).
Current consensus price target is $4.22, suggesting upside of 8.4%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 19.30 cents and EPS of 19.50 cents.
At the last closing share price the estimated dividend yield is 4.96%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 19.95.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 19.7, implying annual growth of -5.7%.
Current consensus DPS estimate is 19.2, implying a prospective dividend yield of 4.9%.
Current consensus EPS estimate suggests the PER is 19.7.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 20.50 cents and EPS of 20.80 cents.
At the last closing share price the estimated dividend yield is 5.27%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 18.70.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 20.3, implying annual growth of 3.0%.
Current consensus DPS estimate is 20.1, implying a prospective dividend yield of 5.2%.
Current consensus EPS estimate suggests the PER is 19.2.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
ASK ABACUS STORAGE KING
REITs – Overnight Price: $1.57
Jarden rates ((ASK)) as Neutral (3) –
Jarden notes Abacus Storage King displayed strong operational performance in the FY25 result, with revenue per available metre and occupancy up, and portfolio value increasing to $2.58bn from $2.41bn.
Additionally, development pipeline looked solid with 101k sqm of new stores and 22k sqm of expansion. The broker expects this to be accretive, with targeted yield on cost of just over 6% over the next 3-plus years.
Debt costs are easing with falling BBSW futures curves providing support. The broker lifted FY26 FFO forecast by 4.2% and FY27 by 9.2%.
Neutral. Target rises to $1.65 from $1.54.
This report was published on August 14, 2025.
Target price is $1.65 Current Price is $1.57 Difference: $0.08
If ASK meets the Jarden target it will return approximately 5% (excluding dividends, fees and charges).
Current consensus price target is $1.64, suggesting upside of 4.7%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 6.20 cents and EPS of 6.80 cents.
At the last closing share price the estimated dividend yield is 3.95%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 23.09.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 6.5, implying annual growth of -70.5%.
Current consensus DPS estimate is 6.3, implying a prospective dividend yield of 4.0%.
Current consensus EPS estimate suggests the PER is 24.2.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 6.60 cents and EPS of 7.20 cents.
At the last closing share price the estimated dividend yield is 4.20%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 21.81.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 6.7, implying annual growth of 3.1%.
Current consensus DPS estimate is 6.4, implying a prospective dividend yield of 4.1%.
Current consensus EPS estimate suggests the PER is 23.4.
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
CBA COMMONWEALTH BANK OF AUSTRALIA
Banks – Overnight Price: $168.17
Jarden rates ((CBA)) as Sell (5) –
CommBank’s FY25 result was slightly below Jarden’s expectations and of lower quality, with around 59% of revenue growth driven by trading gains and derivative valuation adjustments.
The broker highlights a stable net interest margin (NIM) at 2.08% and 3.9% growth in both loans and deposits, though asset quality softened slightly with impaired loans up to 0.97% and provisions down to 1.39%.
Capital remains strong at 12.3%, in the analysts’ opinion, supporting the $2.60 per share final dividend, but buybacks are off the table due to dilution.
Jarden observes Retail and New Zealand weakness offset business and institutional gains, and sees the bank’s valuation as vulnerable to mean reversion. The broker cautions lower rates will erode CBA’s deposit funding advantage while competition intensifies.
Sell. Target cut to $100 from $110.
This report was published on August 13, 2025.
Target price is $100.00 Current Price is $168.17 Difference: minus $68.17 (current price is over target).
If CBA meets the Jarden target it will return approximately minus 41% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $112.81, suggesting downside of -32.9%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 505.00 cents and EPS of 613.00 cents.
At the last closing share price the estimated dividend yield is 3.00%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 27.43.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 633.2, implying annual growth of 4.7%.
Current consensus DPS estimate is 498.6, implying a prospective dividend yield of 3.0%.
Current consensus EPS estimate suggests the PER is 26.6.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 510.00 cents and EPS of 610.10 cents.
At the last closing share price the estimated dividend yield is 3.03%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 27.56.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 665.4, implying annual growth of 5.1%.
Current consensus DPS estimate is 523.3, implying a prospective dividend yield of 3.1%.
Current consensus EPS estimate suggests the PER is 25.3.
Market Sentiment: -1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
EBR EBR SYSTEMS INC
Medical Equipment & Devices – Overnight Price: $1.38
Canaccord Genuity rates ((EBR)) as Buy (1) –
Canaccord Genuity notes the commercial rollout of EBR Systems’ WiSE device is underway after it secured FDA approval in April.
The broker is forecasting around 440 implants in FY26, after three were completed in 2Q25 since the launch. The revenue figures point of average selling price of US$48,690, the broker estimates.
While near-term margins are impacted by launch costs and accounting noise, the long-term pathway to 70% gross margin and 40% operating margin remains intact. Balance sheet strength supports execution.
Buy. Target trimmed to $2.48 from $2.50.
This report was published on August 15, 2025.
Target price is $2.48 Current Price is $1.38 Difference: $1.1
If EBR meets the Canaccord Genuity target it will return approximately 80% (excluding dividends, fees and charges).
The company’s fiscal year ends in December.
Forecast for FY25:
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of minus 13.46 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 10.25.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 15.93 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 8.66.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
EVN EVOLUTION MINING LIMITED
Gold & Silver – Overnight Price: $8.01
Jarden rates ((EVN)) as Underweight (4) –
Evolution Mining’s FY25 results met guidance, with EBITDA of $2.15bn meeting Jarden’s forecast and net profit ahead by 8%. Gearing reduced to 15% following $220m debt repayment.
FY26 production guidance is flat vs FY25 and cost higher but the broker understands the company’s “margin over ounces” strategy while also noting the flat profile comes despite depletion at Mt Rawdon.
The broker commends the capital allocation policy as a right balance between reinvesting in the business, reducing debt and returning cash to shareholders.
FY26 EBITDA forecast cut by -5% and FY27 by -2% on modest cuts to production, and operating and capex forecasts.
Underweight. Target trimmed to $6.05 from $6.18.
This report was published on August 13, 2025.
Target price is $6.05 Current Price is $8.01 Difference: minus $1.96 (current price is over target).
If EVN meets the Jarden target it will return approximately minus 24% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $7.11, suggesting downside of -11.2%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 14.00 cents and EPS of 47.00 cents.
At the last closing share price the estimated dividend yield is 1.75%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 17.04.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 61.6, implying annual growth of 32.5%.
Current consensus DPS estimate is 26.4, implying a prospective dividend yield of 3.3%.
Current consensus EPS estimate suggests the PER is 13.0.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 23.00 cents and EPS of 43.90 cents.
At the last closing share price the estimated dividend yield is 2.87%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 18.25.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 42.0, implying annual growth of -31.8%.
Current consensus DPS estimate is 18.9, implying a prospective dividend yield of 2.4%.
Current consensus EPS estimate suggests the PER is 19.1.
Market Sentiment: -0.7
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
GOZ GROWTHPOINT PROPERTIES AUSTRALIA
Infra & Property Developers – Overnight Price: $2.53
Moelis rates ((GOZ)) as Buy (1) –
Growthpoint Properties Australia’s FY25 result was in line with guidance, Moelis observes, but the highlight was solid leasing momentum in the first six weeks of FY26.
The REIT leased 2.7% of net lettable office area in 2H25 but after balance sheet date leased a further 5.5%.
Moelis explains FY26-27 is largely about addressing the remaining expiry equating to 27% of total income, with the profile from FY28 looking benign.
Gearing rose to 39.7% from 38.8%, and the broker expects it to trend higher if no divestment occurs. EPS forecast for FY26 downgraded by -2.5% and for FY27 by -4.4% on more conservative leasing assumptions for FY26-27.
Buy. Target price $3.09.
This report was published on August 15, 2025.
Target price is $3.09 Current Price is $2.53 Difference: $0.56
If GOZ meets the Moelis target it will return approximately 22% (excluding dividends, fees and charges).
Current consensus price target is $2.43, suggesting downside of -4.1%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Moelis forecasts a full year FY26 dividend of 18.40 cents and EPS of 23.30 cents.
At the last closing share price the estimated dividend yield is 7.27%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 10.86.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 20.3, implying annual growth of N/A.
Current consensus DPS estimate is 18.4, implying a prospective dividend yield of 7.3%.
Current consensus EPS estimate suggests the PER is 12.5.
Forecast for FY27:
Moelis forecasts a full year FY27 dividend of 18.20 cents and EPS of 23.80 cents.
At the last closing share price the estimated dividend yield is 7.19%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 10.63.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 20.6, implying annual growth of 1.5%.
Current consensus DPS estimate is 19.0, implying a prospective dividend yield of 7.5%.
Current consensus EPS estimate suggests the PER is 12.3.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
IAG INSURANCE AUSTRALIA GROUP LIMITED
Insurance – Overnight Price: $8.84
Jarden rates ((IAG)) as Neutral (3) –
Jarden notes Insurance Australia Group reported a strong FY25 result, with reported net profit beating its forecast by 2.3% and the consensus by 3.4%.
The insurance trading margin met the top end of guidance range, thanks to a beat on underlying insurance trading ratio margin, natural hazards benefit and reserve release. Gross written premium growth was 4.3% and the insurer guided to low to mid-single digit growth in FY26.
The broker sees modest margin deterioration in the near term due to lower investment yield but sees cost-out programs supportive of margins from FY27.
FY26 EPS forecast lifted by 0.1% and FY27 by 1%. Neutral. Target rises to $8.50 from $8.45.
This report was published on August 13, 2025.
Target price is $8.50 Current Price is $8.84 Difference: minus $0.34 (current price is over target).
If IAG meets the Jarden target it will return approximately minus 4% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $9.03, suggesting upside of 2.2%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 32.00 cents and EPS of 42.80 cents.
At the last closing share price the estimated dividend yield is 3.62%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 20.65.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 44.5, implying annual growth of -22.6%.
Current consensus DPS estimate is 27.3, implying a prospective dividend yield of 3.1%.
Current consensus EPS estimate suggests the PER is 19.9.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 34.00 cents and EPS of 46.20 cents.
At the last closing share price the estimated dividend yield is 3.85%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 19.13.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 47.2, implying annual growth of 6.1%.
Current consensus DPS estimate is 29.8, implying a prospective dividend yield of 3.4%.
Current consensus EPS estimate suggests the PER is 18.7.
Market Sentiment: 0.2
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
IFT INFRATIL LIMITED
Wealth Management & Investments – Overnight Price: $10.93
Jarden rates ((IFT)) as Buy (1) –
CDC Data Centres is adding 200W to its capacity by developing a data centre in Perth, supported by AUKUS-driven demand for AI and security workloads. Stage one is expected to be operational in 2026.
Infratil owns 49.76% of CDC, and the valuation of its stake was around $6.75bn on June 30, with next update expected in September.
Jarden expects the new CDC project to be brought forward to under construction status in the near term.
Buy. Target unchanged at NZ$14.31
This report was published on August 13, 2025.
Current Price is $10.93. Target price not assessed.
Current consensus price target is N/A
The company’s fiscal year ends in March.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 12.24 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 89.30.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 21.6, implying annual growth of N/A.
Current consensus DPS estimate is 18.7, implying a prospective dividend yield of 1.7%.
Current consensus EPS estimate suggests the PER is 50.6.
Forecast for FY27:
Jarden forecasts a full year FY27 EPS of 4.66 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 234.65.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 32.3, implying annual growth of 49.5%.
Current consensus DPS estimate is 19.4, implying a prospective dividend yield of 1.8%.
Current consensus EPS estimate suggests the PER is 33.8.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
LAM LARAMIDE RESOURCES LIMITED
Uranium – Overnight Price: $0.64
Canaccord Genuity rates ((LAM)) as Speculative Buy (1) –
Laramide Resources ended 1H25 with CA$0.85m cash which is expected to have gone up after CA$12m share placement on July 31.
Canaccord Genuity notes the highlights during the half included the La Jara Mesa and Crownpoint-Churchrock uranium projects being accepted under the US’s FAST-41 approval framework.
In Australia, the Westmoreland received mineral development licence, enabling the progress to feasibility studies and mining lease preparations.
Speculative Buy. Target rises to $1.30 from $1.25.
This report was published on August 15, 2025.
Target price is $1.30 Current Price is $0.64 Difference: $0.66
If LAM meets the Canaccord Genuity target it will return approximately 103% (excluding dividends, fees and charges).
The company’s fiscal year ends in December.
Forecast for FY25:
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of minus 3.71 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 17.24.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 5.72 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 11.18.
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
LGI LGI LIMITED
Overnight Price: $4.34
Canaccord Genuity rates ((LGI)) as Buy (1) –
Canaccord Genuity notes LGI’s FY25 underlying EBITDA came out in the middle of guidance range but was weighted to 2H25, which underpinned strong guidance for FY26.
The company has plans for a 19% uplift in capacity (Belrose BESS), accelerating generation, and supportive carbon/renewable credit markets. The broker sees scope for further re-rating.
FY26 revenue forecast largely unchanged but FY27 cut by -3%. Target rises to $4.30 from $3.50 on valuation roll-forward and capacity boost expected in outer years. Buy retained.
This report was published on August 12, 2025.
Target price is $4.30 Current Price is $4.34 Difference: minus $0.04 (current price is over target).
If LGI meets the Canaccord Genuity target it will return approximately minus 1% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $4.35, suggesting upside of 0.2%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 2.50 cents and EPS of 9.90 cents.
At the last closing share price the estimated dividend yield is 0.58%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 43.84.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 9.9, implying annual growth of 35.8%.
Current consensus DPS estimate is 2.9, implying a prospective dividend yield of 0.7%.
Current consensus EPS estimate suggests the PER is 43.8.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 2.50 cents and EPS of 11.70 cents.
At the last closing share price the estimated dividend yield is 0.58%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 37.09.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 12.6, implying annual growth of 27.3%.
Current consensus DPS estimate is 3.6, implying a prospective dividend yield of 0.8%.
Current consensus EPS estimate suggests the PER is 34.4.
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
LNW LIGHT & WONDER INC
Gaming – Overnight Price: $138.02
Canaccord Genuity rates ((LNW)) as Buy (1) –
The Australasian Gaming Expo confirmed to Canaccord Genuity robust demand trends and industry health, giving confidence Light & Wonder can recover Australian momentum and hit FY25 guidance.
With a strong content slate, visibility in Asia, and healthy sector investment, the broker believes the medium-term outlook remains favourable.
Management is on track to deliver FY25 adjusted EBITDA target of US$1.43-1.47bn, the broker believes.
Buy. Target unchanged at $191.
This report was published on August 14, 2025.
Target price is $191.00 Current Price is $138.02 Difference: $52.98
If LNW meets the Canaccord Genuity target it will return approximately 38% (excluding dividends, fees and charges).
Current consensus price target is $188.67, suggesting upside of 36.7%(ex-dividends)
The company’s fiscal year ends in December.
Forecast for FY25:
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of 764.23 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 18.06.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 924.2, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 14.9.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 875.62 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 15.76.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 1156.3, implying annual growth of 25.1%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 11.9.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
Jarden rates ((LNW)) as Buy (1) –
Light & Wonder’s investor session and Australian product showcase reaffirmed to Jarden its strengthened position in the A&NZ market. Sustained market share of more than 25% is now considered achievable.
The company reiterated 2025 guidance for earnings (EBITDA) of US$1.43bn-US$1.47bn and profit of US$550m-US$575m, alongside its 2028 target for US$2bn earnings. A more than doubling of EPSA to above US$10.55 per share is also expected.
The broker suggests recent share price weakness stems from US delisting and hedge fund activity rather than fundamentals. Forecasts imply low-double-digit earnings growth, rising recurring revenues and free cash flow conversion.
While these forecasts remain below management’s 2028 aspirations, they suggest to Jarden above-market growth and improving earnings quality.
The broker maintains a Buy rating and $183 target price.
This report was published on August 13, 2025.
Target price is $183.00 Current Price is $138.02 Difference: $44.98
If LNW meets the Jarden target it will return approximately 33% (excluding dividends, fees and charges).
Current consensus price target is $188.67, suggesting upside of 36.7%(ex-dividends)
The company’s fiscal year ends in December.
Forecast for FY25:
Jarden forecasts a full year FY25 dividend of 0.00 cents and EPS of 759.59 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 18.17.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 924.2, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 14.9.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 0.00 cents and EPS of 934.72 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 14.77.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 1156.3, implying annual growth of 25.1%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 11.9.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
MAP MICROBA LIFE SCIENCES LIMITED
Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $0.09
Canaccord Genuity rates ((MAP)) as Resume at Buy (1) –
Following a period of research restriction, Canaccord Genuity resumed coverage of Microba Life Sciences with a Buy rating.
The broker revised forecasts to account for recent capital raise and 4Q25 update. FY25 revenue grew 30% y/y on strong 4Q rebound following 3Q mix shift, leading to record 4Q test sales of 3,451, up 88% y/y.
The company raised $14.5m via $12.5m placement and $2m share purchase plan, with Sonic Healthcare ((SHL)) committing up to $8.3m.
Upside risks include faster adoption in AU/UK, especially MetaPanel uptake by high-volume clinics and MAP-315 monetisation, with a potential deal not included in forecasts.
Target trimmed to 19c from 26c.
This report was published on August 14, 2025.
Target price is $0.19 Current Price is $0.09 Difference: $0.1
If MAP meets the Canaccord Genuity target it will return approximately 111% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY25:
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of minus 3.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 3.00.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 2.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 4.50.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
NAN NANOSONICS LIMITED
Medical Equipment & Devices – Overnight Price: $4.02
Canaccord Genuity rates ((NAN)) as Buy (1) –
Canaccord Genuity assessed 1Q26 result of Steris for implication for Nanosonics, noting the result bodes well for the latter’s upcoming FY25 result.
Steris update showed strong capital equipment growth and normalisation of hospital ordering patterns, and the broker concludes capital renewal cycles in hospital is well and truly happening. Trophon3 is expected to benefit as older units get upgraded.
Investors are also eyeing Coris’ launch which is widely seen as a FY27 story.
Buy. Target unchanged at $5.15, with the broker highlighting the stock has a history of strong reaction to earnings.
This report was published on August 12, 2025.
Target price is $5.15 Current Price is $4.02 Difference: $1.13
If NAN meets the Canaccord Genuity target it will return approximately 28% (excluding dividends, fees and charges).
Current consensus price target is $4.66, suggesting upside of 16.0%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY25:
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of 5.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 80.40.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 6.2, implying annual growth of 44.9%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 64.8.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 7.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 57.43.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 7.4, implying annual growth of 19.4%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 54.3.
Market Sentiment: 0.1
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
ORA ORORA LIMITED
Paper & Packaging – Overnight Price: $2.32
Jarden rates ((ORA)) as Upgrade to Buy from Overweight (1) –
Jarden notes Orora’s FY25 result showed the Saverglass unit has stabilised, beating consensus, with the overall result broadly in line.
FY26 outlook surprised to the upside, with Australasia Cans EBIT in line with consensus, Gawler slightly lower but Saverglass better than expected.
The broker reckons lower capex is a big positive for cash flow, and while consensus may need to temper FY26 NPAT expectations, the stabilisation at Saverglass and cash generation should underpin confidence.
Target rises to $2.60 from $2.35 on DCF assumption revisions, lower capex and roll-forward. Rating upgraded to Buy from Overweight.
This report was published on August 14, 2025.
Target price is $2.60 Current Price is $2.32 Difference: $0.28
If ORA meets the Jarden target it will return approximately 12% (excluding dividends, fees and charges).
Current consensus price target is $2.34, suggesting upside of 0.9%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 10.10 cents and EPS of 13.60 cents.
At the last closing share price the estimated dividend yield is 4.35%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 17.06.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 13.5, implying annual growth of 25.5%.
Current consensus DPS estimate is 9.9, implying a prospective dividend yield of 4.3%.
Current consensus EPS estimate suggests the PER is 17.2.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 12.50 cents and EPS of 16.80 cents.
At the last closing share price the estimated dividend yield is 5.39%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 13.81.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 14.7, implying annual growth of 8.9%.
Current consensus DPS estimate is 10.9, implying a prospective dividend yield of 4.7%.
Current consensus EPS estimate suggests the PER is 15.8.
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
ORE OREZONE GOLD CORPORATION REGISTERED
Overnight Price: $1.24
Canaccord Genuity rates ((ORE)) as Buy (1) –
Canaccord Genuity has a Buy rating and $2.50 target price for Orezone Gold. The company’s 2Q25 adjusted EBITDA of US$45.5m compared with the broker’s forecast of US$46m and the consensus of US$50m.
Cost of US$1,830/oz was 1% higher than the broker’s estimate and up 29% q/q due to external factors including higher royalties and lower grid power availability.
The company reiterated FY25 production guidance, and completed $75m ASX IPO.
This report was published on August 14, 2025.
Target price is $2.50 Current Price is $1.24 Difference: $1.26
If ORE meets the Canaccord Genuity target it will return approximately 102% (excluding dividends, fees and charges).
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
ORG ORIGIN ENERGY LIMITED
Infrastructure & Utilities – Overnight Price: $12.78
Jarden rates ((ORG)) as Neutral (3) –
Jarden assessed Origin Energy’s FY25 result to be broadly in line and therefore thinks the strong share price reaction was a bit overdone.
Underlying EBITDA was in line with the broker’s forecast and the consensus, though underlying net profit was 4% ahead of the broker’s forecast and 1% ahead of the consensus.
FY26 EBITDA guidance for energy markets was $1.4-1.7bn which was $300m higher than initial guidance for FY25, but -3% below the broker’s estimate. APLNG guidance was unchanged vs July update, and Octopus’ performance was below the broker’s forecast.
The broker lifted FY26 EPS forecast by 6.5% and FY27 by 7.4% on higher energy market EBITDA and lower forecast depreciation.
Neutral. Target price $11.70.
This report was published on August 14, 2025.
Target price is $11.70 Current Price is $12.78 Difference: minus $1.08 (current price is over target).
If ORG meets the Jarden target it will return approximately minus 8% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $11.57, suggesting downside of -9.5%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 60.00 cents and EPS of 75.90 cents.
At the last closing share price the estimated dividend yield is 4.69%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 16.84.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 68.7, implying annual growth of -20.3%.
Current consensus DPS estimate is 60.8, implying a prospective dividend yield of 4.8%.
Current consensus EPS estimate suggests the PER is 18.6.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 60.00 cents and EPS of 80.00 cents.
At the last closing share price the estimated dividend yield is 4.69%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 15.97.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 72.1, implying annual growth of 4.9%.
Current consensus DPS estimate is 63.7, implying a prospective dividend yield of 5.0%.
Current consensus EPS estimate suggests the PER is 17.7.
Market Sentiment: 0.2
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
PLS PILBARA MINERALS LIMITED
New Battery Elements – Overnight Price: $2.20
Canaccord Genuity rates ((PLS)) as Buy (1) –
Canaccord Genuity was one of 55 participants visiting Pilbara Minerals’ Pilgangoora lithium operation, underscoring ongoing interest in Tier 1 lithium operators despite near-term market headwinds.
The broker observed significant progress has been achieved over the past 12 months.
Despite weak lithium prices and subdued sector sentiment, the company strategically deployed part of its large cash balance into site expansion and operational improvements. The operation will make the company among the lowest-cost, best-run spodumene producers globally, the broker highlights.
The Ngungaju plant remains under care & maintenance and requires around 4 months lead time for restart. The company didn’t provide restart capex guidance, but the broker estimates -$20-30m will be needed.
Buy. Target price $2.70.
This report was published on August 13, 2025.
Target price is $2.70 Current Price is $2.20 Difference: $0.5
If PLS meets the Canaccord Genuity target it will return approximately 23% (excluding dividends, fees and charges).
Current consensus price target is $1.83, suggesting downside of -16.9%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY25:
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of minus 23.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 9.57.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is -1.1, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is N/A.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 2.00 cents and EPS of 3.00 cents.
At the last closing share price the estimated dividend yield is 0.91%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 73.33.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is -0.4, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is N/A.
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
PME PRO MEDICUS LIMITED
Medical Equipment & Devices – Overnight Price: $313.50
Moelis rates ((PME)) as Hold (3) –
Moelis notes Pro Medicus’ FY25 result was in line with expectations but the story is about FY26, with strong revenue base established from recently secured contracts.
New business wins in FY25 exceeded the prior record by over two times, and Visage’s US radiology market penetration is estimated at 10%, up from 7% in FY24.
The company aims to enter the pathology market later in 2025, and, for now, the broker reckons the opportunity is undefined.
The broker increased revenue forecasts, leading to earnings rise and a lift in target price to $341.99 from $323.69.
Hold maintained.
This report was published on August 14, 2025.
Target price is $341.99 Current Price is $313.50 Difference: $28.49
If PME meets the Moelis target it will return approximately 9% (excluding dividends, fees and charges).
Current consensus price target is $300.27, suggesting downside of -4.2%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Moelis forecasts a full year FY26 dividend of 77.00 cents and EPS of 159.30 cents.
At the last closing share price the estimated dividend yield is 0.25%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 196.80.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 152.6, implying annual growth of 38.4%.
Current consensus DPS estimate is 76.6, implying a prospective dividend yield of 0.2%.
Current consensus EPS estimate suggests the PER is 205.4.
Forecast for FY27:
Moelis forecasts a full year FY27 dividend of 94.00 cents and EPS of 200.40 cents.
At the last closing share price the estimated dividend yield is 0.30%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 156.44.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 202.0, implying annual growth of 32.4%.
Current consensus DPS estimate is 107.5, implying a prospective dividend yield of 0.3%.
Current consensus EPS estimate suggests the PER is 155.2.
Market Sentiment: -0.2
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
Wilsons rates ((PME)) as Upgrade to Overweight from Market Weight (1) –
Wilsons notes Pro Medicus’s FY25 result was solid on revenue and outstanding on margin leverage, showing it can lift profits while penetrating larger US integrated delivery networks.
Total addressable market for cardiology was lifted to 670m scans, of which 85% is serviceable in full-stack model. Digital pathology was confirmed for FY26 and the broker views it as offering future upside optionality.
Minimal changes to the broker’s revenue forecasts but margin is conservatively expected to increase by 60bps in FY26 and 76bps in FY27.
Target lifted to $350 from $325. Rating upgraded to Overweight from Market Weight.
This report was published on August 15, 2025.
Target price is $350.00 Current Price is $313.50 Difference: $36.5
If PME meets the Wilsons target it will return approximately 12% (excluding dividends, fees and charges).
Current consensus price target is $300.27, suggesting downside of -4.2%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Wilsons forecasts a full year FY26 dividend of 74.30 cents and EPS of 150.30 cents.
At the last closing share price the estimated dividend yield is 0.24%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 208.58.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 152.6, implying annual growth of 38.4%.
Current consensus DPS estimate is 76.6, implying a prospective dividend yield of 0.2%.
Current consensus EPS estimate suggests the PER is 205.4.
Forecast for FY27:
Wilsons forecasts a full year FY27 dividend of 102.50 cents and EPS of 205.00 cents.
At the last closing share price the estimated dividend yield is 0.33%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 152.93.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 202.0, implying annual growth of 32.4%.
Current consensus DPS estimate is 107.5, implying a prospective dividend yield of 0.3%.
Current consensus EPS estimate suggests the PER is 155.2.
Market Sentiment: -0.2
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
RHC RAMSAY HEALTH CARE LIMITED
Healthcare services – Overnight Price: $39.19
Jarden rates ((RHC)) as Neutral (3) –
Jarden notes Australia’s private hospital sector continues to face a number of challenges, including on the costs front, but Ramsay Health Care is among the standouts because it owns its hospitals.
A recent positive was private health insurance negotiations which resulted in indexation close to inflation rate. Wage costs is a key issue but the recent enterprise agreements with nurses in NSW and WA provides some optimism on EBIT margin expansion.
Negotiations at other states are pending but another positive for now is nurse-to-patient ratio demand has not been accepted. The broker trimmed underlying net profit forecast for FY25 by -0.8% but lifted FY26 by 0.6% while lowering FY27 by -0.9%.
Ahead of FY25 result, the broker is 1.7% ahead of consensus for underlying net profit. The broker sees some possibility of FY26 guidance but even without it, it sees negative revisions to consensus underlying net profit growth of 21.8% vs its 14.3% forecast.
Neutral. Target rises to $46.55 from $44.58.
This report was published on August 13, 2025.
Target price is $46.55 Current Price is $39.19 Difference: $7.36
If RHC meets the Jarden target it will return approximately 19% (excluding dividends, fees and charges).
Current consensus price target is $38.46, suggesting downside of -1.9%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY25:
Jarden forecasts a full year FY25 dividend of 76.10 cents and EPS of 125.20 cents.
At the last closing share price the estimated dividend yield is 1.94%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 31.30.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 122.4, implying annual growth of -67.9%.
Current consensus DPS estimate is 71.8, implying a prospective dividend yield of 1.8%.
Current consensus EPS estimate suggests the PER is 32.0.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 87.50 cents and EPS of 144.20 cents.
At the last closing share price the estimated dividend yield is 2.23%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 27.18.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 159.3, implying annual growth of 30.1%.
Current consensus DPS estimate is 101.8, implying a prospective dividend yield of 2.6%.
Current consensus EPS estimate suggests the PER is 24.6.
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
S32 SOUTH32 LIMITED
Mining – Overnight Price: $2.96
Canaccord Genuity rates ((S32)) as Hold (3) –
South32 stated it is not confident the Mozal aluminium smelter will have sufficient and affordable power once the current agreement expires in March 2026.
While Canaccord Genuity still sees the potential for a power deal to be struck, the probabability is waning as time goes on. The broker reckons it is not the end of the story and the company’s decision to put the smelter on care and maintenance is a good strategy.
FY26 production guidance is now 240kt vs the broker’s 360kt estimate, and impairment of -US$372m will be recognised in the FY25 result.
Hold. Target price $2.60.
This report was published on August 14, 2025.
Target price is $2.60 Current Price is $2.96 Difference: minus $0.36 (current price is over target).
If S32 meets the Canaccord Genuity target it will return approximately minus 12% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $3.47, suggesting upside of 17.1%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY25:
Canaccord Genuity forecasts a full year FY25 dividend of 8.82 cents and EPS of 20.87 cents.
At the last closing share price the estimated dividend yield is 2.98%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 14.18.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 22.9, implying annual growth of N/A.
Current consensus DPS estimate is 9.5, implying a prospective dividend yield of 3.2%.
Current consensus EPS estimate suggests the PER is 12.9.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 5.72 cents and EPS of 12.66 cents.
At the last closing share price the estimated dividend yield is 1.93%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 23.39.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 30.7, implying annual growth of 34.1%.
Current consensus DPS estimate is 9.8, implying a prospective dividend yield of 3.3%.
Current consensus EPS estimate suggests the PER is 9.6.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
SGM SIMS LIMITED
Steel & Scrap – Overnight Price: $15.05
Jarden rates ((SGM)) as Neutral (3) –
Sims has signed an MOU with Alter Steel to supply ferrous scrap to its proposed 500ktpa electric arc furnace project at Pinkenba in Queensland, targeted for commissioning in 2027.
Jarden sees this as a significant move considering surplus regional steel capacity. The company has an approval for initial -$40m capex over FY26-27 to expand Pinkenba into a logistics hub.
Separately and ahead of FY25 result on August 18, the broker will look for North American trading performance, surplus land value unlocking and cost-out and capital management plans.
Neutral. Target rises to $15.40 from $14.70 on Pinkenba-related earnings changes and roll-forward.
This report was published on August 1, 2025.
Target price is $15.40 Current Price is $15.05 Difference: $0.35
If SGM meets the Jarden target it will return approximately 2% (excluding dividends, fees and charges).
Current consensus price target is $14.66, suggesting downside of -2.6%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY25:
Jarden forecasts a full year FY25 dividend of 25.40 cents and EPS of 39.10 cents.
At the last closing share price the estimated dividend yield is 1.69%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 38.49.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 46.3, implying annual growth of N/A.
Current consensus DPS estimate is 22.0, implying a prospective dividend yield of 1.5%.
Current consensus EPS estimate suggests the PER is 32.5.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 46.90 cents and EPS of 69.70 cents.
At the last closing share price the estimated dividend yield is 3.12%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 21.59.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 89.4, implying annual growth of 93.1%.
Current consensus DPS estimate is 34.3, implying a prospective dividend yield of 2.3%.
Current consensus EPS estimate suggests the PER is 16.8.
Market Sentiment: 0.1
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
SUN SUNCORP GROUP LIMITED
Insurance – Overnight Price: $21.01
Jarden rates ((SUN)) as Overweight (2) –
Jarden notes stronger investment returns offset softer gross written premiums growth for Suncorp Group, leading to a FY25 general insurance net profit beat.
The broker reckons the key feature was a lift in natural hazard allowance by 13% relative to 6% exposure growth, which tilts risk towards favourable catastrophe experience in FY26.
The company announced $400m share buyback to run from Sep-26 to June -26, with potential for continuation into FY27.
The broker cut FY26 net profit forecast by -0.5% and FY27 by -0.9%.
Overweight. Target unchanged at $22.
This report was published on August 14, 2025.
Target price is $22.00 Current Price is $21.01 Difference: $0.99
If SUN meets the Jarden target it will return approximately 5% (excluding dividends, fees and charges).
Current consensus price target is $22.65, suggesting upside of 7.8%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 85.00 cents and EPS of 118.90 cents.
At the last closing share price the estimated dividend yield is 4.05%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 17.67.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 118.3, implying annual growth of -15.6%.
Current consensus DPS estimate is 87.4, implying a prospective dividend yield of 4.2%.
Current consensus EPS estimate suggests the PER is 17.8.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 88.00 cents and EPS of 123.60 cents.
At the last closing share price the estimated dividend yield is 4.19%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 17.00.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 125.7, implying annual growth of 6.3%.
Current consensus DPS estimate is 92.2, implying a prospective dividend yield of 4.4%.
Current consensus EPS estimate suggests the PER is 16.7.
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
TAH TABCORP HOLDINGS LIMITED
Gaming – Overnight Price: $0.72
Jarden rates ((TAH)) as Overweight (2) –
Tabcorp Holdings’ FY25 result on Aug 27 marks the first full year result under new CEO Gill McLachlan and CFO Mark Howell, and Jarden notes peer results indicated challenging market conditions remain.
The broker will focus on cost savings delivery and momentum heading into FY26 plus any disclosure changes aligned with new leadership team structure. Leverage is estimated to be 2.2x, within the tolerable limit of less than 2.5x, hence low likelihood of equity raising.
The broker is -2% below consensus on FY25 EPS forecast, despite estimating modestly higher operating profits.
Overweight. Target unchanged at 75c.
This report was published on August 14, 2025.
Target price is $0.75 Current Price is $0.72 Difference: $0.03
If TAH meets the Jarden target it will return approximately 4% (excluding dividends, fees and charges).
Current consensus price target is $0.74, suggesting upside of 3.2%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY25:
Jarden forecasts a full year FY25 dividend of 1.50 cents and EPS of 1.60 cents.
At the last closing share price the estimated dividend yield is 2.08%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 45.00.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 1.9, implying annual growth of N/A.
Current consensus DPS estimate is 1.2, implying a prospective dividend yield of 1.7%.
Current consensus EPS estimate suggests the PER is 37.9.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 1.60 cents and EPS of 2.60 cents.
At the last closing share price the estimated dividend yield is 2.22%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 27.69.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 2.8, implying annual growth of 47.4%.
Current consensus DPS estimate is 1.7, implying a prospective dividend yield of 2.4%.
Current consensus EPS estimate suggests the PER is 25.7.
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
TLS TELSTRA GROUP LIMITED
Telecommunication – Overnight Price: $4.88
Jarden rates ((TLS)) as Downgrade to Neutral from Overweight (3) –
Jarden assesses Telstra Group’s FY25 result as mixed, with EBITDA delivering growth of 5% y/y but underlying momentum in core portfolios weaker than expected.
Postpaid active users rose by a weaker than expected 4k in 2H and prepaid users fell -68k. Wholesale pricing and active users showed decent growth, and the broker believes this is key to grow earnings and manage decline in prepaid users.
FY26 EPS forecast trimmed by -4% and FY27 by -2% on negative mobile subscriber mix, higher satellite-related costs and deteriorating international business momentum.
Target cut to $4.80 from $4.90. Rating downgraded to Neutral from Overweight.
This report was published on August 14, 2025.
Target price is $4.80 Current Price is $4.88 Difference: minus $0.08 (current price is over target).
If TLS meets the Jarden target it will return approximately minus 2% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $4.87, suggesting downside of -0.1%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 20.00 cents and EPS of 20.50 cents.
At the last closing share price the estimated dividend yield is 4.10%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 23.80.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 20.5, implying annual growth of 8.7%.
Current consensus DPS estimate is 20.2, implying a prospective dividend yield of 4.1%.
Current consensus EPS estimate suggests the PER is 23.8.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 21.50 cents and EPS of 22.10 cents.
At the last closing share price the estimated dividend yield is 4.41%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 22.08.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 22.1, implying annual growth of 7.8%.
Current consensus DPS estimate is 21.2, implying a prospective dividend yield of 4.3%.
Current consensus EPS estimate suggests the PER is 22.1.
Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
TPW TEMPLE & WEBSTER GROUP LIMITED
Furniture & Renovation – Overnight Price: $25.03
Canaccord Genuity rates ((TPW)) as Buy (1) –
Canaccord Genuity notes Temple & Webster now has higher ambition to become the largest furniture and homewares retailer, from aiming to be the largest online retailer.
FY25 result showed an acceleration of revenue at the end of 4Q25 which continued into 1Q26. June-August revenue grew 28% compared with 21% growth in FY25.
The broker notes the company entered FY26 in a strong financial position, and supportive macroeconomic environment will result in another strong growth year.
FY26-27 revenue forecasts lifted by 1% and 2%, respectively.
After lifting from rating review, the broker assigned Buy rating and target price of $30.50.
This report was published on August 15, 2025.
Target price is $30.50 Current Price is $25.03 Difference: $5.47
If TPW meets the Canaccord Genuity target it will return approximately 22% (excluding dividends, fees and charges).
Current consensus price target is $23.76, suggesting downside of -5.1%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 11.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 227.55.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 25.8, implying annual growth of 171.0%.
Current consensus DPS estimate is 8.6, implying a prospective dividend yield of 0.3%.
Current consensus EPS estimate suggests the PER is 97.0.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 17.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 147.24.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 34.7, implying annual growth of 34.5%.
Current consensus DPS estimate is 11.5, implying a prospective dividend yield of 0.5%.
Current consensus EPS estimate suggests the PER is 72.1.
Market Sentiment: 0.2
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
Jarden rates ((TPW)) as Buy (1) –
Jarden describes Temple & Webster’s FY25 result as strong but messy, with EBITDA beating by 5% and sales update pointing to a strong FY26. However, the accounting understated FY25 revenue while overstating EBITDA.
Irrespective, the broker has a positive view and sees tailwinds for both demand and margins in FY26 on excess factory capacity, lesser headwind from forex and interest rate cuts.
FY26-28 EBITDA forecasts increased by 5-7%, though net profit forecasts were lowered on D&A increases due to lease accounting as a finance one, rather than operating.
Target price rises to $32.79 from $25.16. Buy retained.
This report was published on August 15, 2025.
Target price is $32.79 Current Price is $25.03 Difference: $7.76
If TPW meets the Jarden target it will return approximately 31% (excluding dividends, fees and charges).
Current consensus price target is $23.76, suggesting downside of -5.1%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 0.00 cents and EPS of 14.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 178.79.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 25.8, implying annual growth of 171.0%.
Current consensus DPS estimate is 8.6, implying a prospective dividend yield of 0.3%.
Current consensus EPS estimate suggests the PER is 97.0.
Forecast for FY27:
Jarden forecasts a full year FY27 EPS of 22.10 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 113.26.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 34.7, implying annual growth of 34.5%.
Current consensus DPS estimate is 11.5, implying a prospective dividend yield of 0.5%.
Current consensus EPS estimate suggests the PER is 72.1.
Market Sentiment: 0.2
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
Petra Capital rates ((TPW)) as Buy (1) –
Petra Capital observes the highlight of Temple & Webster’s FY25 result was the strong sales momentum in June that spilled over to FY26.
Sales growth from July 1-Aug 11 was up 28% y/y, the same as June, but up from around 18% growth experienced in the first five months. EBITDA margin of 3.1% beat the broker’s 2.9% forecast, with FY26 guided to be 3-5%.
The broker forecasts 23.7% y/y sales growth in FY26, with upside risk, and a further acceleration to 25.3% growth in FY27. EBITDA margin is estimated at 4%, also with upside risk.
Buy. Target rises to $30 from $20.
This report was published on August 15, 2025.
Target price is $30.00 Current Price is $25.03 Difference: $4.97
If TPW meets the Petra Capital target it will return approximately 20% (excluding dividends, fees and charges).
Current consensus price target is $23.76, suggesting downside of -5.1%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Petra Capital forecasts a full year FY26 dividend of 0.00 cents and EPS of 12.70 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 197.09.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 25.8, implying annual growth of 171.0%.
Current consensus DPS estimate is 8.6, implying a prospective dividend yield of 0.3%.
Current consensus EPS estimate suggests the PER is 97.0.
Forecast for FY27:
Petra Capital forecasts a full year FY27 dividend of 0.00 cents and EPS of 24.30 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 103.00.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 34.7, implying annual growth of 34.5%.
Current consensus DPS estimate is 11.5, implying a prospective dividend yield of 0.5%.
Current consensus EPS estimate suggests the PER is 72.1.
Market Sentiment: 0.2
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
TWE TREASURY WINE ESTATES LIMITED
Food, Beverages & Tobacco – Overnight Price: $7.82
Jarden rates ((TWE)) as Overweight (2) –
Jarden highlights Treasury Wine Estates delivered 17% EBITS growth in FY25 to $770m despite external challenges, and announced a $200m share buyback.
The broker has an optimistic view on the stock based on the Penfolds brand being the core value driver, but notes earnings challenges from US distributor changes. Weaker China trading and new CEO also add to the uncertainty.
FY26-28 EPS forecasts trimmed by -3% to -4% after assuming EBITS growth of 6% in FY26 (based on guidance), with Penfolds EBITS expected to grow 10%.
The broker believes the stock’s re-rating will require clear execution strategy from the new CEO and stabilisation of key markets.
Overweight. Target trimmed to $9.20 from $10.00.
This report was published on August 13, 2025.
Target price is $9.20 Current Price is $7.82 Difference: $1.38
If TWE meets the Jarden target it will return approximately 18% (excluding dividends, fees and charges).
Current consensus price target is $8.88, suggesting upside of 13.6%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 46.00 cents and EPS of 60.90 cents.
At the last closing share price the estimated dividend yield is 5.88%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 12.84.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 61.4, implying annual growth of 14.0%.
Current consensus DPS estimate is 42.3, implying a prospective dividend yield of 5.4%.
Current consensus EPS estimate suggests the PER is 12.7.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 53.00 cents and EPS of 71.10 cents.
At the last closing share price the estimated dividend yield is 6.78%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 11.00.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 68.9, implying annual growth of 12.2%.
Current consensus DPS estimate is 46.9, implying a prospective dividend yield of 6.0%.
Current consensus EPS estimate suggests the PER is 11.3.
Market Sentiment: 0.2
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
VAU VAULT MINERALS LIMITED
Gold & Silver – Overnight Price: $0.43
Moelis rates ((VAU)) as Buy (1) –
Twelve months since the merger of Red 5 and Silver Lake Resources created Vault Minerals, Moelis visited the King of the Hills mining operation in Western Australian.
The broker notes a shift in strategy to bulk tonnage approach from high-grade mining, with mine life extended to 20 years.
After a full review, the broker adjusted mining rate, opex and capex, and also lifted D&A to better reflect 1H run rates, while pushing back the anticipated restart of Sugar Zone to FY28.
Buy. Target cut to 69c from 73c.
This report was published on August 15, 2025.
Target price is $0.69 Current Price is $0.43 Difference: $0.26
If VAU meets the Moelis target it will return approximately 60% (excluding dividends, fees and charges).
Current consensus price target is $0.59, suggesting upside of 36.4%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY25:
Moelis forecasts a full year FY25 dividend of 0.00 cents and EPS of 3.10 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 13.87.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 3.6, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 11.9.
Forecast for FY26:
Moelis forecasts a full year FY26 dividend of 0.00 cents and EPS of 4.70 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 9.15.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 4.2, implying annual growth of 16.7%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 10.2.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
VGL VISTA GROUP INTERNATIONAL LIMITED
Software & Services – Overnight Price: $2.98
Canaccord Genuity rates ((VGL)) as Buy (1) –
Vista International reported annual recurring revenue of NZ$146m at the 1H25 result, in line with Canaccord Genuity’s forecast. Revenue rose 11% to NZ$77m largely driven by recurring revenue increase.
The broker reckons the highlight was capitalised R&D spend of -NZ$40m over the next 2-3 years, up from -NZ$25m, which will help accelerate the cloud migration process,
FY25 revenue was guided to the bottom of the previous NZ$167-173m, but EBITDA margin guidance was maintained. Annual recurring revenue target of over NZ$175m was also pushed out to FY26.
2025 EBITDA forecast cut by -5% and 2026 by -10%. Buy. Target unchanged at $4.
This report was published on August 14, 2025.
Target price is $4.00 Current Price is $2.98 Difference: $1.02
If VGL meets the Canaccord Genuity target it will return approximately 34% (excluding dividends, fees and charges).
Current consensus price target is $4.10, suggesting upside of 37.6%(ex-dividends)
The company’s fiscal year ends in December.
Forecast for FY25:
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of 2.83 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 105.23.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 3.3, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 90.3.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 4.93 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 60.42.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 5.9, implying annual growth of 78.8%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 50.5.
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
Jarden rates ((VGL)) as Overweight (2) –
Vista International’s 1H25 result showed a big target needs to be achieved in the 2H to meet the FY25 target of 1,600 sites, which Jarden believes is clearly optimistic.
The company is ramping investment to accelerate adoption, with capex guidance lifted to a peak of -NZ$40m from -NZ$25m in FY25. It described it as a pull forward of required spend, but the broker is taking a conservative approach and lifting capex estimates.
Earnings forecasts downgraded in the short term on expectations of delay in site transitions through FY25-26.
Target unchanged at NZ$3.80 as roll-forward and lower risk-free rate assumption offset earnings revisions. Overweight retained.
This report was published on August 14, 2025.
Current Price is $2.98. Target price not assessed.
Current consensus price target is $4.10, suggesting upside of 37.6%(ex-dividends)
The company’s fiscal year ends in December.
Forecast for FY25:
Jarden forecasts a full year FY25 dividend of 0.00 cents and EPS of 2.28 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 130.47.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 3.3, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 90.3.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 0.00 cents and EPS of 6.30 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 47.28.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 5.9, implying annual growth of 78.8%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 50.5.
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
VNT VENTIA SERVICES GROUP LIMITED
Industrial Sector Contractors & Engineers – Overnight Price: $5.50
Canaccord Genuity rates ((VNT)) as Buy (1) –
Ventia Services’ 1H25 revenue and underlying EBITDA missed Canaccord Genuity’s forecasts but EBITDA margin of 8.3% was ahead of the broker’s 8.2% forecast and 8.1% consensus.
Work in hand was up $4.3bn to $20.6bn due to strong contract wins. The company upgraded FY25 net profit forecast to 10-12% growth from 7-10% on strong earnings momentum from contract wins and margin expansion.
FY25 EBITDA forecast trimmed -1% but net profit forecast lifted by 1.5%.
Buy. Target increases to $5.65 from $4.88.
This report was published on August 15, 2025.
Target price is $5.65 Current Price is $5.50 Difference: $0.15
If VNT meets the Canaccord Genuity target it will return approximately 3% (excluding dividends, fees and charges).
Current consensus price target is $5.15, suggesting downside of -6.4%(ex-dividends)
The company’s fiscal year ends in December.
Forecast for FY25:
Canaccord Genuity forecasts a full year FY25 dividend of 23.00 cents and EPS of 30.00 cents.
At the last closing share price the estimated dividend yield is 4.18%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 18.33.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 30.2, implying annual growth of 17.3%.
Current consensus DPS estimate is 22.4, implying a prospective dividend yield of 4.1%.
Current consensus EPS estimate suggests the PER is 18.2.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 25.00 cents and EPS of 33.00 cents.
At the last closing share price the estimated dividend yield is 4.55%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 16.67.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 32.5, implying annual growth of 7.6%.
Current consensus DPS estimate is 23.9, implying a prospective dividend yield of 4.3%.
Current consensus EPS estimate suggests the PER is 16.9.
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
WAF WEST AFRICAN RESOURCES LIMITED
Gold & Silver – Overnight Price: $2.77
Canaccord Genuity rates ((WAF)) as Buy (1) –
West African Resources published a 10-year outlook targeting average production of 480kozpa across Sanbrado and Kiaka in Burkina Faso, with peak production of 569koz in 2029. Average for 2029-31 is over 500koz.
The plan showed Sanbrado mine life extension to 2035 but Kiaka compressed to 2042 vs 2024, though with higher throughput.
Canaccord Genuity believes the upgrades and new mine areas positions the company for robust growth, making it one of the top five ASX-listed gold producers by 2029.
Buy. Target rises to $5.00 from $4.70, with the valuation now risked 80% for Sanbrado and 70% for Kiaka.
This report was published on August 14, 2025.
Target price is $5.00 Current Price is $2.77 Difference: $2.23
If WAF meets the Canaccord Genuity target it will return approximately 81% (excluding dividends, fees and charges).
The company’s fiscal year ends in December.
Forecast for FY25:
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of 29.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 9.55.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 12.00 cents and EPS of 79.00 cents.
At the last closing share price the estimated dividend yield is 4.33%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 3.51.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
WBC WESTPAC BANKING CORPORATION
Banks – Overnight Price: $36.81
Jarden rates ((WBC)) as Underweight (4) –
Jarden notes Westpac’s 3Q25 net interest margin rose 5bps to 1.85% due mainly to a reduction in liquid assets, replicating portfolio benefit and 1bps from NZ loans.
Cash net profit rose 8% q/q to $1.9bn but the broker expects higher costs and bad debts in 4Q, along with lower other operating income.
The broker notes the appointment of Carolyn McCann as chief executive for consumer bank means the bank has leadership in place to execute the UNITE project, though highlights it carries significant risks.
No change to EPS forecasts. Underweight with unchanged target price of $30.
This report was published on August 14, 2025.
Target price is $30.00 Current Price is $36.81 Difference: minus $6.81 (current price is over target).
If WBC meets the Jarden target it will return approximately minus 19% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $30.70, suggesting downside of -16.6%(ex-dividends)
The company’s fiscal year ends in September.
Forecast for FY25:
Jarden forecasts a full year FY25 dividend of 153.00 cents and EPS of 198.00 cents.
At the last closing share price the estimated dividend yield is 4.16%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 18.59.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 200.8, implying annual growth of -0.0%.
Current consensus DPS estimate is 153.0, implying a prospective dividend yield of 4.2%.
Current consensus EPS estimate suggests the PER is 18.3.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 155.00 cents and EPS of 196.00 cents.
At the last closing share price the estimated dividend yield is 4.21%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 18.78.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 203.3, implying annual growth of 1.2%.
Current consensus DPS estimate is 159.6, implying a prospective dividend yield of 4.3%.
Current consensus EPS estimate suggests the PER is 18.1.
Market Sentiment: -0.7
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
Disclaimer:
The content of this information does in no way reflect the opinions of FNArena, or of its journalists. In fact we don’t have any opinion about the stock market, its value, future direction or individual shares. FNArena solely reports about what the main experts in the market note, believe and comment on. By doing so we believe we provide experienced, intelligent investors with a valuable tool that helps them in making up their own minds, reading market trends and getting a feel for what is happening beneath the surface.
This document is provided for informational purposes only. It does not constitute an offer to sell or a solicitation to buy any security or other financial instrument. FNArena employs very experienced journalists who base their work on information believed to be reliable and accurate, though no guarantee is given that the daily report is accurate or complete. Investors should contact their personal adviser before making any investment decision.
<span style="
Click to view our Glossary of Financial Terms
CHARTS
For more info SHARE ANALYSIS: 360 - LIFE360 INC
For more info SHARE ANALYSIS: AGN - ARGENICA THERAPEUTICS LIMITED
For more info SHARE ANALYSIS: ALK - ALKANE RESOURCES LIMITED
For more info SHARE ANALYSIS: AOV - AMOTIV LIMITED
For more info SHARE ANALYSIS: ARF - ARENA REIT
For more info SHARE ANALYSIS: ASK - ABACUS STORAGE KING
For more info SHARE ANALYSIS: CBA - COMMONWEALTH BANK OF AUSTRALIA
For more info SHARE ANALYSIS: EBR - EBR SYSTEMS INC
For more info SHARE ANALYSIS: EVN - EVOLUTION MINING LIMITED
For more info SHARE ANALYSIS: GOZ - GROWTHPOINT PROPERTIES AUSTRALIA
For more info SHARE ANALYSIS: IAG - INSURANCE AUSTRALIA GROUP LIMITED
For more info SHARE ANALYSIS: IFT - INFRATIL LIMITED
For more info SHARE ANALYSIS: LAM - LARAMIDE RESOURCES LIMITED
For more info SHARE ANALYSIS: LGI - LGI LIMITED
For more info SHARE ANALYSIS: LNW - LIGHT & WONDER INC
For more info SHARE ANALYSIS: MAP - MICROBA LIFE SCIENCES LIMITED
For more info SHARE ANALYSIS: NAN - NANOSONICS LIMITED
For more info SHARE ANALYSIS: ORA - ORORA LIMITED
For more info SHARE ANALYSIS: ORE - OREZONE GOLD CORPORATION REGISTERED
For more info SHARE ANALYSIS: ORG - ORIGIN ENERGY LIMITED
For more info SHARE ANALYSIS: PLS - PILBARA MINERALS LIMITED
For more info SHARE ANALYSIS: PME - PRO MEDICUS LIMITED
For more info SHARE ANALYSIS: RHC - RAMSAY HEALTH CARE LIMITED
For more info SHARE ANALYSIS: S32 - SOUTH32 LIMITED
For more info SHARE ANALYSIS: SGM - SIMS LIMITED
For more info SHARE ANALYSIS: SHL - SONIC HEALTHCARE LIMITED
For more info SHARE ANALYSIS: SUN - SUNCORP GROUP LIMITED
For more info SHARE ANALYSIS: TAH - TABCORP HOLDINGS LIMITED
For more info SHARE ANALYSIS: TLS - TELSTRA GROUP LIMITED
For more info SHARE ANALYSIS: TPW - TEMPLE & WEBSTER GROUP LIMITED
For more info SHARE ANALYSIS: TWE - TREASURY WINE ESTATES LIMITED
For more info SHARE ANALYSIS: VAU - VAULT MINERALS LIMITED
For more info SHARE ANALYSIS: VGL - VISTA GROUP INTERNATIONAL LIMITED
For more info SHARE ANALYSIS: VNT - VENTIA SERVICES GROUP LIMITED
For more info SHARE ANALYSIS: WAF - WEST AFRICAN RESOURCES LIMITED
For more info SHARE ANALYSIS: WBC - WESTPAC BANKING CORPORATION